stockportfolio.pro
Amneal Pharmaceuticals, Inc. P/E Ratio 2016–2025
Amneal Pharmaceuticals, Inc. (AMRX) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +25.4%/yr over 9 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 57.27 | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | 68.43 | +813.4% |
| FY 2020 | 7.49 | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
Source: Amneal Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Amneal Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAmneal Pharmaceuticals, Inc. — frequently asked questions
What is Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio?
Amneal Pharmaceuticals, Inc. (AMRX) reported price-to-earnings ratio of 57.27 for fiscal year 2025, per its SEC filings.
How has Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2016 and 2025, AMRX's price-to-earnings ratio grew at roughly 25.4% per year (compound annual rate), from 7.49 to 57.27.
Where does this data come from?
Figures are computed from Amneal Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.